AzTrials
AzTrials

Postbariatric HypoglycemiaNCT06896682

Cortisol and Obesity - A Vicious Cycle? Hypoglycemia After Bariatric Surgery - Association With Cortisol Metabolism?

An observational study of Postbariatric Hypoglycemia, run by Esbjerg Hospital - University Hospital of Southern Denmark at 1 site in Denmark.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this observational study is to learn about how bariatric surgery affects the metabolism of cortisol. The main question it aims to answer is whether changes in cortisol contribute to the development of reactive hypoglycemia? 100 individuals who have previously undergone bariatric surgery, are planned to be… Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Postbariatric Hypoglycemia
How many people
100 participants
Where
1 siteDenmark
Study dates
8 Jul 2025to 31 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: postbariatric patients

Who may be able to join

  • Participants must have undergone one of the following bariatric procedures at least 12 months prior:
  • Roux-en-Y gastric bypass
  • Gastric sleeve

Who cannot join

  • Pregnancy and breastfeeding
  • Nephrotic syndrome (kidney disease with protein loss in urine), liver cirrhosis, or severe malnutrition, as these conditions reduce cortisol-binding globulin (CBG) levels, affecting total cortisol concentration
  • Use of corticosteroid medications, such as prednisolone
  • Use of opiod-containing medication
  • Use of medications containing estrogen, such as hormone therapy for menopause
  • Known adrenal disease affecting cortisol metabolism, including autonomous cortisol production and Cushing's syndrome
  • Diabetes that does not require medical treatment
  • Previously diagnosed reactive hypoglycemia after bariatric surgery requiring medical treatment

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Charlotte R Stolberg, MD PhD contact

+4579183127

charlotte.ron.stolberg@rsyd.dk

Denmark1 site, 1 recruiting
  • Esbjerg Hospital

    Esbjerg, 6700

    Recruiting

Other trials in Denmark

About this study

The goal of this observational study is to learn about how bariatric surgery affects the metabolism of cortisol.

The main question it aims to answer is whether changes in cortisol contribute to the development of reactive hypoglycemia?

100 individuals who have previously undergone bariatric surgery, are planned to be included.

Read the detailed description

Purpose The project investigates how bariatric surgery affects the metabolism of cortisol. Additionally, it examines whether changes in cortisol contribute to the development of reactive hypoglycemia, a serious complication observed after bariatric surgery.

Study Visits

Visit 1:

At the first visit, participants sign an informed consent form, complete a medical history questionnaire, undergo measurements (height, weight), and have blood samples taken. They also undergo an adrenal stimulation test (ACTH test), receive a continuous glucose monitor (CGM), and complete a questionnaire about hypoglycemia symptoms.

The CGM is a small device that continuously measures blood glucose levels via a tiny sensor placed on the skin, typically on the arm or abdomen.

The ACTH test is performed after the participant has rested for at least 15 minutes. A synthetic hormone (Synacthen) is injected to stimulate the adrenal glands to produce cortisol. Blood samples are collected immediately before the injection and again 30 minutes afterward. The visit is expected to last approximately 1 hour.

Participants wear the CGM until the second visit and are instructed to collect 24-hour urine samples. If they experience hypoglycemia symptoms between visits, they take a saliva sample for cortisol measurement 5 minutes after symptom onset and another exactly 24 hours later.

Visit 2:

Ten days after the first visit, participants return for the second visit, where they submit their 24-hour urine and saliva samples. They then undergo a three-hour extended meal test.

This test consists of consuming a standardized liquid meal (200 ml Nutridrink, containing per 100 ml: 150 kcal, 5.8 g fat, 18.4 g carbohydrates, and 5.9 g protein). While undergoing the meal test, participants continue wearing the CGM, have blood samples taken at 30-minute intervals, and complete another questionnaire on hypoglycemia. This visit is expected to last 4 hours, bringing the total expected study time to 5 hours.

Monitoring and Reporting To ensure participant safety throughout the study, the following procedures will be implemented to manage potential complications.

Participants will be closely monitored during all procedures, including blood sampling, the ACTH test, and the meal test. Any side effects or complications will be documented and reported to the principal investigator.

Emergency Preparedness Emergency medical equipment, allergy management supplies, and trained nurses will be available during all visits. The nurses are trained to handle cases of post-bariatric hypoglycemia. In the event of severe allergic reactions or other acute complications, immediate medical treatment will be provided, and the principal investigator will be contacted immediately.

Informed Consent Participants will receive detailed information about potential risks and side effects before the study begins. They will be encouraged to report any discomfort or side effects immediately.

Follow-up Participants will have the opportunity to contact the principal investigator between and after visits if they experience any issues or have questions.

Protocol for Study Discontinuation If a participant experiences severe complications, their participation in the study will be discontinued, and they will receive appropriate medical care as outlined above, along with follow-up observation until they are in stable condition. The principal investigator will assess the situation and adjust the study protocol if necessary to prevent further complications.

Financial Aspects The project is funded through research grants from the Region of Southern Denmark. No financial compensation is provided to participants, except for reimbursement of transportation costs.

Keywords
cortisol, bariatric surgery, postbariatric hypoglycemia

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in serum cortisol during mixed meal test

    cortisol at nadir glucose during the mixed meal test - cortisol at the start of the meal test

    Measured: 0, 30, 60, 90, 120, 150, 180 minutes (visit 2)

Secondary outcomes (3)
  1. ACTH test: Test of adrenal function

    0 min: Cortisol and corticotropin 30 min: Cortisol, corticotropin Δ Cortisol (30-minute cortisol - 0-minute cortisol) Bloodsamples

    Measured: 0, 30 minutes

  2. Cortisol hormone profile

    Bloodsamples of CBG, Cortisol, Cortisone

    Measured: 1 hour

  3. urinary cortisol: Ratio of cortisol/cortisone

    24-hour urinary cortisol: Ratio of cortisol/cortisone Urine sampling for 24 hour

    Measured: 24 hour

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Mar 2025
  2. Study start8 Jul 2025
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06896682
Sponsor's protocol ID
VEK Projekt-ID S-20250006
Status last verified
Mar 2025
First submitted
3 Mar 2025
Last updated
13 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Postbariatric Hypoglycemia, run by Esbjerg Hospital - University Hospital of Southern Denmark at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Charlotte R Stolberg, MD PhD (+4579183127, charlotte.ron.stolberg@rsyd.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in serum cortisol during mixed meal test (time frame: 0, 30, 60, 90, 120, 150, 180 minutes (visit 2)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in